UPDATE: Stifel Reiterates Buy Rating, Lowers PT on Tekmira Pharmaceuticals Corporation Ahead of Analyst Day

In a report published Friday, Stifel analyst Stephen Willey reiterated a Buy rating on Tekmira Pharmaceuticals Corporation TKMR, but lowered the price target from $31.00 to $26.00. In the report, Stifel noted, “We expect the November 21st analyst day to provide additional granularity around incremental pipeline updates. Disclosure of DoD funding for TKM-Ebola-Guinea manufacturing/scale-up is an incremental positive. Reduced target price of $26 (previously $31) reflects increased risk-adjustments for TKM-PLK1 and Ebola-related monetization.” Tekmira Pharmaceuticals Corporation closed on Thursday at $15.76.